# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Guggenheim analyst Subbu Nambi upgrades Guardant Health (NASDAQ:GH) from Neutral to Buy and announces $36 price target.
Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $30 ...
Upgraded gene panel on tissue genomic profiling test covers 498 biomarkers, including guideline-recommended genesOperational im...
Jefferies analyst Tycho Peterson initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Tar...
Data from study using Guardant360® blood test show Black patients with PIK3CA mutations in advanced breast cancer were less lik...
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc ...